



Frozen shoulder

Neal L. Millar¹✉, Adam Meakins², Filip Struyf³, Elaine Willmore⁴,
Abigail L. Campbell⁵, Paul D. Kirwan⁶, Moeed Akbar¹, Laura Moore⁷,
Jonathan C. Ronquillo⁸, George A. C. Murrell⁹ and Scott A. Rodeo⁷

Abstract | Frozen shoulder is a common debilitating disorder characterized by shoulder pain and progressive loss of shoulder movement. Frozen shoulder is frequently associated with other systemic conditions or occurs following periods of immobilization, and has a protracted clinical course, which can be frustrating for patients as well as health-care professionals. Frozen shoulder is characterized by fibroproliferative tissue fibrosis, whereby fibroblasts, producing predominantly type I and type III collagen, transform into myofibroblasts (a smooth muscle phenotype), which is accompanied by inflammation, neoangiogenesis and neoinnervation, resulting in shoulder capsular fibrotic contractures and the associated clinical stiffness. Diagnosis is heavily based on physical examination and can be difficult depending on the stage of disease or if concomitant shoulder pathology is present. Management consists of physiotherapy, therapeutic modalities such as steroid injections, anti-inflammatory medications, hydrodilatation and surgical interventions; however, their effectiveness remains unclear. Facilitating translational science should aid in development of novel therapies to improve outcomes among individuals with this debilitating condition.

Frozen shoulder¹ (FS), also known as adhesive capsulitis, is a common shoulder disorder manifesting as pain and progressive loss of shoulder movement. FS can be either primary or secondary, which refers to whether the condition has come on spontaneously with no known cause or trauma (primary FS), or whether it is associated with trauma, surgery or other pathology, such as subacromial pain (secondary FS). FS typically progresses through three overlapping stages, with the predominant symptoms of pain and loss of motion (inflammation/‘freezing’ (stage I)), stiffness (‘frozen’ (stage II)) and then resolution of symptoms (‘thawing’ (stage III)). However, this classification remains contentious, as many patients still experience symptoms and functional restrictions long after progression through these stages.

FS is characterized by fibroproliferative tissue fibrosis (FIG. 1) of the shoulder capsule, which is thought to be modulated by mediators that include cytokines, growth factors and enzymes, in particular, matrix metalloproteinases (MMPs), with increasing evidence for the involvement of inflammatory mediators and various immune cells. The histological characteristic of FS is the presence of a matrix of fibroblasts and myofibroblasts containing type I and type III collagen that results in an imbalance between tissue extracellular matrix (ECM) degradation, remodelling and regeneration. Although knowledge of risk factors of FS, pathophysiology and enhanced treatments are still emerging, both basic and clinical research (and consequently therapeutic advances) lag behind that in other

musculoskeletal conditions, such as inflammatory arthritis and osteoarthritis.

A true evidence-based model for the management of FS has yet to be defined, with a wide spectrum of treatments available. Management varies according to the stage of the disease and range from early pharmacotherapy and associated physiotherapy to later approaches such as surgery (manipulation under anaesthesia (MUA) and arthroscopic capsular release (ACR)), extracorporeal shockwave therapy (ESWT), hydrodilatation, injections (sodium hyaluronate injection), collagenase treatment and experimental approaches that require validation in clinical trials. FS therefore remains a challenge to treat, with a large proportion of patients still failing to attain complete resolution of symptoms. Indeed, while FS is often regarded as a self-limiting disease (1–2 year recovery), various studies have shown that many of the symptoms associated with FS, such as stiffness and pain, persist in 20–50% of patients^{2–4}. Thus, further work is required to identify more effective treatment options for these patients. This Primer presents the current knowledge of the basic and clinical science of FS and highlights its clinical presentation, natural history, risk factors, pathoanatomy and pathogenesis. Furthermore, we provide evidence-based treatment guidelines in the form of a proposed treatment algorithm. In addition, we aim to consolidate and interpret the unmet needs in the field and discuss the barriers that need to be overcome to attain better outcomes for all patients with FS.

✉e-mail: neal.millar@glasgow.ac.uk
<https://doi.org/10.1038/s41572-022-00386-2>

Author addresses

¹School of Infection and Immunity, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

²Department of Trauma and Orthopaedics, West Hertfordshire Hospital Trust, Watford, UK.

³Department of Rehabilitation Sciences and Physiotherapy, University of Antwerp, Antwerp, Belgium.

⁴Physiotherapy Department, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.

⁵Department of Orthopaedic Surgery, Kaiser Permanente West Los Angeles, Los Angeles, CA, USA.

⁶School of Medicine, Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.

⁷Department of Orthopaedic Surgery, Sports Medicine and Shoulder Service, Hospital for Special Surgery, New York, NY, USA.

⁸De La Salle University Medical Center, Health Sciences Institute & Asian Hospital and Medical Center, Dasmariñas, Philippines.

⁹Orthopaedic Research Institute, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia.

Epidemiology**Prevalence**

The lifetime prevalence of FS is estimated to be 2–5% of the general population, and FS affects ~8% of men and ~10% of women^{5,6}. FS is most common in the fifth and sixth decades of life, with the peak age in the mid-50s⁷. In up to 17% of patients with FS, the other shoulder becomes affected within 5 years^{4,8}.

It is debatable whether FS as a condition is truly unique to the shoulder. Indeed, there are case reports of occurrences of adhesive capsulitis in the knee, hip and ankle^{9,10}, although they are exceptionally rare. Contractures and fibrosis do frequently occur in the knee and elbow, although without the potential for the spontaneous resolution seen in the shoulder.

Risk factors

FS has been linked to a range of co-morbidities, including cardiovascular disease, Parkinson disease, stroke, hyperthyroidism and, in particular, diabetes mellitus, where the incidence of FS can reach close to 60%^{11–14}. FS has also been linked to hypothyroidism¹⁵, hyperlipidaemia¹⁶ and autoimmune diseases¹⁷. These co-morbidities are found in more than 80% of individuals diagnosed with FS, with over 35% of affected individuals having more than three associated conditions¹¹. Other risk factors (BOX 1) associated with FS are smoking¹⁸, obesity⁷ and low levels of physical activity¹⁹. In addition, FS risk is increased in individuals with Dupuytren disease, a fibrotic disorder of the palmar fascia that has a very similar pathophysiology to FS^{20–22}. In addition to an association with metabolic and hormonal changes, FS has also been associated with abnormal shoulder mechanics and nerve dysfunction. This link between primary nerve dysfunction and FS was first proposed in 1959 by Thompson and Kopell²³, who proposed that reduced glenohumeral motion could result in exacerbated scapulothoracic motion, thereby stretching the suprascapular nerve, leading to a cycle of pain and shoulder dysfunction. Since then, FS has been identified in patients with a variety of primary neurological conditions. FS is a cause of shoulder pain and dysfunction in patients after radical neck dissection²⁴, acute cerebrovascular aneurysm surgery and subarachnoid haemorrhage²⁵ and in individuals with Parkinson

disease²⁶. Furthermore, FS, as identified by shoulder capsule volume on arthrography, is the leading cause of hemiplegic shoulder pain after stroke²⁷.

Mechanisms/pathophysiology**From homeostasis to disease**

The shoulder joint capsule is a lax fibrous sheath that encloses the joint. The healthy capsule is collagenous in structure, composed primarily of dense type I collagen and elastic fibre bundles with limited vessels and nerve fibres. The main cell type within this membrane is fibroblasts, which maintain capsule health by producing ECM proteins that provide a supportive yet flexible structure.

In FS, the typical collagen structure is disrupted by gradual fibrosis of this connective tissue membrane and thickening of the adjacent synovial membrane²⁸. These fibrotic changes are accompanied by inflammation, neo-angiogenesis and neoinnervation^{29–32}. The consequence is a reduced joint volume and increased stiffness of the capsule that cause restricted movement and pain. In the following sections we describe how the shoulder capsule and associated structures progress from a lax fibrous membrane to a fibrotic hypervascular structure that drives the clinical course of FS.

Stages of FS

FS progresses through three characteristic stages¹, each with associated arthroscopic and histological changes³². Neviasser and Neviasser initially described four stages of disease (stages I–IV) in 1987 (REF¹), which was modified in 2010 to three clinically based stages (stages I–III)³³ (FIG. 2). Stage I is characterized by pain without appreciable limitation in motion, and is associated with an inflammatory synovial reaction on arthroscopy, and with hypervascular synovitis with rare inflammatory cell infiltrates and normal capsular tissue on biopsy. Clinically, stage II involves ongoing pain with progressive limitation in motion. Intra-articularly, there is ongoing synovitis and progressive capsular contracture. On arthroscopy, there is hypervascular synovitis and loss of axillary folding. Histology shows hypertrophic, hypervascular synovitis now with perivascular and sub-synovial scar formation. Stage III is marked by ongoing stiffness clinically, and is associated with loss of the axillary recess, fibrosis and minimal synovitis on arthroscopy. Biopsy of patients with stage III FS reveals dense, hypercellular collagenous tissue to mature fibrosis with a thin synovial layer, similar to other fibrosing conditions.

Inflammation

Recent years have seen the musculoskeletal scientific community direct its attention to investigating the mechanisms underlying the inflammatory and fibrotic changes associated with FS to elucidate the aetiological, cellular and molecular pathways. Although a single unifying cause is yet to be identified, several key mechanisms have been implicated in the pathogenesis of FS. One of these is chronic, unresolved inflammation. Histological analyses of tissue biopsy samples from affected patients consistently reveal chronic inflammation, which is associated with increased vascularity, fibroblast proliferation, synovial membrane thickening and increased ECM deposition^{7,8}.




a Healthy shoulder**b Early-stage frozen shoulder****c Late-stage frozen shoulder**

Fig. 1 | Structural changes during frozen shoulder. a | The healthy capsule is collagenous in structure, composed primarily of dense type I collagen and elastic fibre bundles with limited blood vessels and nerve fibres. The main cell type within this membrane is the fibroblast, which maintains capsule health by producing extracellular matrix (ECM) proteins that provide a supportive yet flexible structure. **b** | In frozen shoulder, there is fibrosis and thickening of the connective tissue membrane as well as the adjacent synovial membrane. **c** | Fibroproliferation results in an increased number of fibroblasts producing more ECM proteins, resulting in a dense and poorly organized fibrillar structure. These fibrotic changes are accompanied by inflammation, neoangiogenesis and neoinnervation. The consequence is a reduced joint volume and increased stiffness of the capsule, causing restricted movement and pain.

Various immune cells have been identified in capsular tissue from patients with FS, including B cells, macrophages, mast cells and T cells^{34–36}. There is growing evidence indicating a reciprocal homeostatic relationship between immune cells and stromal cells within soft tissue, in both health and disease, and as we enter the single-cell genomic age, there are emerging data of the presence of discrete subtypes of immune cells in the capsule of patients with FS, including several subpopulations of dendritic and T cells³⁷. Immune cells and their mediators have been implicated in driving the progression of many fibrotic disorders, and there are now the beginnings of a greater appreciation for their role in soft tissue diseases. While it is simple to explain the presence of immune cells in a purely pathological context, their homeostatic and inflammation-resolving role in soft tissues is now evident. For example, a subtype of macrophages (those expressing *LYVE1* and *MERTK*) has been identified in patients with rheumatoid arthritis who are in remission³⁸ that is phenotypically similar to a population of macrophages present in healthy shoulder capsule but reduced in the capsule of patients with FS³⁷. Loss of these homeostatic or resolutive cells could indicate a function for these macrophages in maintaining healthy tissue.

Pro-inflammatory cytokines

As FS has been described historically as a chronic fibrotic disease of the shoulder capsule, the main emphasis of cytokine studies has been on the role of TGF β . Many studies have unequivocally implicated TGF β in fibrotic disease, and FS is no exception. TGF β is highly expressed in FS tissue³⁹ and can induce numerous cellular fibrotic responses, including ECM protein production, fibroblast proliferation, increased myofibroblast differentiation and collagen gel contractility⁴⁰. The link to fibrosis is discussed later in this section. Other inflammatory mediators, including IL-1, IL-6, IL-10, GM-CSF, M-CSF, PDGF and TNF, are also dysregulated in diseased capsule^{35,41} and may drive inflammatory and matrix responses. Fibroblasts cultured from diseased capsule produce elevated levels of pro-inflammatory cytokines (such as IL-6, IL-8 and CCL-20) in comparison with the levels produced by healthy capsular fibroblasts⁴².

Evidence suggests a prominent role for IL-17A in FS. FS tissue contains T cells (CD4⁺ and CD8⁺ T cells, among other subtypes), which produce IL-17A, whereas T cells are predominantly absent from healthy shoulder capsule³⁷. In this study, IL-17A induced greater

pro-fibrotic and inflammatory responses in FS fibroblasts than in fibroblasts from healthy tissue as a result of greater levels of the IL-17A signalling receptor (IL-17RA) on fibroblasts from diseased shoulders. The potential pathological effects of IL-17A are notable due to its similar effect observed in tendinopathy⁴³, for which anti-IL-17A treatment (secukinumab) is currently being investigated in a clinical trial⁴⁴.

The levels of IL-33, which can also act as an alarmin (also known as a damage-associated molecular pattern), are also elevated in FS tissue⁴⁵. Alarmin release has been described in other chronic musculoskeletal conditions, such as rheumatoid arthritis and osteoarthritis^{46,47}. A study examined H&E-stained capsular tissue from patients with FS and found fibroblastic hypercellularity and increased vascularity as well as high levels of the alarmins IL-33, high-mobility group protein B1 (HMGB1), S100A8 and S100A9; the levels of these alarmins were correlated with the severity of patient-reported pain⁴⁵. These alarmins can be released from immune and stromal cells and may mediate crosstalk between the two compartments.

Advanced glycation end products (AGEs) have been associated with inflammation, and the increased production and accumulation of these products is seen in diabetes and routine ageing. AGEs can act as immune modulators by attracting cells that release pro-inflammatory cytokines to coordinate degradation and renewal of ECM. Capsular tissue of patients with FS had higher immunoreactivity, blood vessel formation and perivascular adipocytes than healthy capsule tissue⁴⁸.

Neural and vascular changes

The hypervascularity associated with inflammation has also been suggested to play a key role in the development of FS symptoms¹⁸. Hypervascularity is prominent across histological studies in FS, particularly in the rotator interval⁸. This is the result of neovascularisation, which is demonstrated by overexpression of the haematopoietic cell surface marker CD34 (REF.⁴²) and vascular endothelial growth factor (VEGF) in both patients with FS who have diabetes and those without diabetes²¹. Neovascularisation is accompanied by neurogenesis, which is probably driven by increased expression of the nerve growth factor receptor p75 (REF.³⁰). In patients with FS, the degree of neoinnervation is correlated with the frequency of night pain and expression of HMGB1 (REF.⁴⁵). In addition to an increase in the density of nerves, there is also an increase in acid-sensing ion channels (ASICs), calcitonin gene-related peptide (CGRP) and substance P⁴⁹, which are upregulated in hyperalgesia and chronic pain. CGRP in particular is a key connection between the nervous and immune systems. CGRP is released by the synaptic terminals of pain sensing neurons and acts on lymphocytes, macrophages and mast cells, among others⁴⁹, resulting in increased production of pro-inflammatory mediators and further immune cell recruitment. In addition, expression of the melatonin receptors MTNR1A and MTNR1B is upregulated in FS in response to the pro-inflammatory cytokines TNF and IL-1 β ⁵⁰, which in turn induces ASIC3 and IL-6 expression, leading to further pain and inflammation. Combined, these features might explain why pain,

Box 1 | Risk factors for frozen shoulder

Systemic risk factors	<ul style="list-style-type: none"> • Humeral fracture • Parkinson disease • Axillary surgery (breast carcinoma) • Radiotherapy
<ul style="list-style-type: none"> • Diabetes mellitus • Hypothyroidism • Hyperthyroidism • Hypoadrenalism • Hyperlipidaemia 	Intrinsic risk factors
Extrinsic risk factors	<ul style="list-style-type: none"> • Rotator cuff tendinopathy • Rotator cuff tears • Biceps tendinopathy • Calcific tendinopathy • Acromioclavicular arthritis
<ul style="list-style-type: none"> • Cardiopulmonary disease • Cervical degenerative disc disease • Cerebrovascular disease 	




Fig. 2 | **The stages of frozen shoulder.** Frozen shoulder is classified into three clinical stages based on pain level and the severity of range of motion (ROM) limitation. Stage I is the inflammatory stage and includes gradually worsening pain but limited effect on ROM. Stage II involves plateauing of shoulder pain levels but is mostly associated with increasing stiffness that results in considerable loss of shoulder function that particularly affects patients' normal activities of daily living. Stage III is characterized by reduction of pain (particularly night pain), with pain usually at the end of ROM, and a very gradual improvement in stiffness over a number of months to years.

particularly night pain, is such a prominent feature of FS. Central sensitization in FS has not been comprehensively studied and so remains speculative, but could explain why some patients are resistant to current interventions and may benefit from a different approach.

Matrix changes

Fibrosis is the fundamental process manifesting in FS. Fibroblasts are the resident cell type within the joint capsule and are responsible for producing the ECM that forms the structure of the tissue. Under normal homeostatic conditions, type I collagen is the primary matrix protein produced, whereas the more immature and disorganized type III collagen³⁹ is deposited under pathological conditions, owing to the requirement for accelerated ECM turnover. In addition, the production of several other structural matrix proteins is increased in FS, including vimentin, fibronectin and tenascin C⁵¹. Both MMPs and tissue inhibitors of metalloproteinases (TIMPs), which regulate matrix remodelling, are dysregulated in FS. MMPs 1–4, 7–9 and 12–14 and TIMP1 and TIMP2 are implicated in FS⁵¹. These proteinases have a vital role in ECM turnover, with the balance between MMPs and TIMPs crucial in matrix remodelling and homeostasis, as highlighted by the development of FS in 50% of recruited patients in an anticancer treatment trial using a TIMP analogue⁵².

Interestingly, many of the fibrotic facets of FS fibroblasts have been attributed to the effects of increased TGF β production. TGF β has long been known to induce

transdifferentiation of fibroblasts to myofibroblasts, and myofibroblasts are a hallmark of FS and other fibrotic conditions^{53–55}. In addition, there is now a greater appreciation of the potential role of other cytokines, including IL-1, IL-4, IL-13 and IL-17A, in fibrosis. One such aspect of fibrotic disorders that may be under cytokine regulation is the phenomenon of fibroblast activation. Activated fibroblasts show higher expression of CD44, CD55, CD90 (THY1), CD106 (also known as VCAM1), CD248 (also known as endosialin), podoplanin, uridine diphosphate-glucose dehydrogenase, prolyl-4-hydroxylase and prolyl endopeptidase FAP (also known as fibroblast activation protein) compared with control healthy fibroblasts, which are associated with inflammatory cytokine and matrix dysregulation⁴⁴. Elevated expression of these proteins by fibroblasts is a phenotype of several musculoskeletal diseases including FS, and activated pathogenic fibroblasts produce more pro-inflammatory proteins than healthy fibroblasts⁴². However, whether the increased expression of these proteins is itself directly responsible for the pathological effects of activated fibroblasts or whether it is just an epiphenomenon of fibroblast activation remains unclear⁵⁶.

Metabolic factors

Multiple researchers have proposed that certain conditions, such as hyperlipidaemia and hyperglycaemia, predispose patients with FS to propagation of pro-inflammatory and pro-fibrotic signalling cascades. Multiple studies have found a strong association between diabetes mellitus and FS^{57,58}, particularly in the




Fig. 3 | Molecular pathophysiology of frozen shoulder. A trigger, typically systemic (for example, altered metabolic status), extrinsic (for example, shoulder immobilization after trauma or surgery) or intrinsic (rotator cuff pathology), induces a pro-inflammatory, pro-fibrotic environment in which various soluble factors influence cell behaviour. Substance P induces production and release of neuropeptides by mast cells, which affects fibroblast activation and matrix production. Pro-inflammatory cytokines, such as IL-1, IL-6, HMGB1 and IL-17A, and growth factors stimulate fibroblast activation, proliferation and positive feedback loops driving further cytokine and growth factor production. Cytokines also induce T cell activation and production of IL-17A, while the abundance of macrophage subsets, B cells and dendritic cells are all increased in biopsy samples of frozen shoulder in humans. All these factors, together with mechanical stress and matrix turnover imbalance, induce fibroblast transdifferentiation to myofibroblasts, which leads to tissue fibrosis and contracture.

setting of long-term hyperglycaemia⁵⁹. In addition, FS in individuals with diabetes tends to be prolonged and refractory to non-operative treatment compared with that in individuals without diabetes¹³. This association is probably multifactorial, resulting from chronic low-level inflammation in individuals with diabetes as well as the presence of AGEs. Pro-inflammatory cytokines that are consistently elevated in patients with diabetes, including TNF, IL-6 and IL-1 β ⁵¹, are also present at high levels in the capsule and synovium of patients with FS⁸. Furthermore, AGEs show increased immunoreactivity in both patients with FS who have diabetes and those who do not⁴⁸. AGEs contribute to fibrosis and inflammation across other organ systems in individuals with diabetes through multiple mechanisms. First, AGEs form crosslinks between collagen molecules, leading to resistance to proteolysis and reduced tissue compliance⁶⁰. Second, AGEs stimulate the production of pro-inflammatory and pro-fibrotic cytokines and growth factors in stromal and immune cells through activation of the receptor for AGEs⁵⁵. Finally, AGEs may also contribute to the imbalanced MMP and/or TIMP activity that is found across diabetic organ systems⁶¹.

Elevation in serum lipids and cholesterol is also associated with the development of FS, both in conjunction with diabetes and separate from it^{45,62,63}. Inflammatory lipoproteins, which are associated with vascular inflammation and immune reaction, are independent risk factors for the development of FS⁶⁴. Furthermore, the level of increase in serum lipids and glucose is inversely correlated with the Constant score (a measure of patient-reported pain and shoulder function) in patients with early FS⁵⁵, supporting the role of these blood markers in disease progression. Transcriptional profiling of samples from patients with FS (using RNA sequencing) revealed that the greatest differential gene

expression is in the peroxisome proliferator-activated receptor- γ (PPAR γ) pathway⁶⁶, suggesting a central role for altered lipid metabolism in the pathogenesis of FS. Interestingly, patients taking lipid-lowering medications (such as statins) are not at increased risk of developing FS, unlike those taking anti-hyperglycaemic medications¹⁶. This observation suggests that either a reduction in serum lipids or taking lipid-lowering medications might be protective, which is consistent with the known anti-inflammatory and anti-fibrotic effects of statins in other conditions^{62,63}.

In addition to hyperlipidaemia and hyperglycaemia, both hyperthyroidism and hypothyroidism are associated with an increased risk of developing FS⁶⁷. Calcitonin is probably the connection between thyroid dysfunction and FS, as calcitonin deficiency is a feature of both disorders⁶⁸. The connection between calcitonin and FS was first noted when postmenopausal women being treated for osteoporosis with salmon calcitonin showed improvements in their FS symptoms⁶⁹. Salmon calcitonin reduces TGF β , type I collagen and type III collagen synthesis as well as fibroblast adhesion in cultured cells⁷⁰, all of which are key mediators of fibrosis in FS. These results were confirmed in a double-blind, randomized, controlled trial in which intranasal calcitonin treatment improved shoulder pain and function faster than placebo in patients with FS⁶⁸.

In summary, the pathophysiology of FS is not yet clear but accumulating evidence is starting to clarify the roles of inflammation, angiogenesis, neuromodulation and fibrosis in this disease (FIG. 3).

Diagnosis, screening and prevention

Diagnosis

The diagnosis of FS is fraught with ambiguity, inconsistency and confusion for clinicians. Many patients can present with signs and symptoms of FS (pain and

global restriction in movement) but do not have pathological changes of the joint capsule⁷¹. Despite the many diagnostic labels and familiar patterns of presentation with FS, there are currently no formally recognized diagnostic criteria. Consensus studies indicate that pain, particularly at night and with sudden or unexpected movements, along with a global loss of active and passive movement of the shoulder, are reliable clinical identifiers⁷². While these are all undoubtedly characteristic features of FS, they lack sufficient differential diagnostic capability to distinguish FS from other shoulder pathologies (FIG. 4).

Pain in FS is often reported in a wide and diffuse pattern around the shoulder, scapula, chest and into the upper arm, usually above the elbow, which, in its early stages, can make FS indistinguishable from other shoulder pathologies, such as rotator cuff tendinopathy, joint arthrosis and pain from cervicogenic sources. Pain in FS is often described as constant, deep and severe.




Fig. 4 | Proposed algorithm for differential diagnosis of frozen shoulder. This algorithm may aid in differentiating frozen shoulder from other painful and/or motion-limiting conditions of the shoulder, such as glenohumeral joint (GHJ) osteoarthritis, subacromial pain and acromioclavicular joint (ACJ) pathology. Decisions are made based predominantly on physical examination (loss of passive external rotation) but other techniques and methods also provide useful diagnostic information. SLAP, superior labrum from anterior to posterior.

Loss of shoulder range of motion (ROM) is a key feature of FS pathology but objective clinical markers that are deemed to constitute positive findings are rather nebulous.

Clinical assessment. Loss of passive and active ROM is inherently associated with FS but criteria are conflicting. Thresholds range from a reduction of 30% in two of three unspecified directions⁷³, to 50% loss of external rotation compared to the contralateral side⁷⁴. However, there is a lack of reliability in differentiating movement loss from capsule pathology resulting from other potentially more serious pathologies or from self-limiting movement owing to kinesiophobia and protective pain guarding^{71,75,76}.

Reliably and accurately assessing shoulder movement in an individual with severe pain is a clinical challenge. Often, what seems to be an abnormal loss of range can be a patient self-limiting due to pain or fear. It is therefore recommended that movement is assessed in a variety of positions with differing levels of support. For example, the key movement of external rotation, if found to be reduced in the standing position, should also be assessed in the supine or lying position with the arm and trunk supported (FIG. 5). Similarly, assessing shoulder elevation by lifting the arm overhead could be compared with lowering the head and trunk below a supported arm. A noticeable disparity in ROM is more likely to represent kinesiophobia and movement inhibition as opposed to true capsular restriction.


As capsular tissue is non-contractile, isometric muscle testing in the mid-range of movements should elicit little pain provocation in patients with FS (FIG. 5). This can be a useful screening tool when considering other diagnoses such as rotator cuff tendinopathy. Assessment of the cervical spine is also essential to eliminate possible cervicogenic pathology such as nerve root irritation causing radicular pain.

Imaging. The acquisition of plain radiographs of the glenohumeral joint is often suggested to ensure that there are not substantial degenerative joint changes that could also present with pain and motion loss and, therefore, confound the diagnosis of FS. However, in practice, a working diagnosis can often be made on the basis of a good medical history and simple clinical examination, with plain radiographs not necessarily required in primary care environments⁷⁷. It has been suggested that routine radiography may not confer superior accuracy in diagnosing serious pathology to good clinical questioning and physical examination⁷⁸.


The use of advanced imaging modalities such as ultrasonography and MRI to diagnose FS has been proposed. Findings such as axillary capsule thickening and/or obliteration of the axillary recess, coracohumeral ligament and rotator interval thickening, and/or hypervascularity are considered indicative of FS pathology if the imaging results match the clinical presentation^{79,80}. Indeed, advanced imaging in patients with refractory FS can be extremely important in detecting undiagnosed soft tissue tumours, although these undiagnosed tumours are present in fewer than 1% of patients with FS⁷⁶.

Planes of movement of the shoulder joint


Abduction and adduction



Flexion and extension



Horizontal abduction and adduction



Internal and external rotation




Fig. 5 | **Key examination techniques for frozen shoulder.** Various movements of the arm of the affected shoulder are used to assess pain and limitations of range of motion in individuals with frozen shoulder.

However, imaging does not offer superior diagnostic information beyond a medical history and physical examination and is therefore not recommended for routine work-up⁸¹; however, MRI may be useful if there is a clinical suspicion of another serious pathology with similar symptomatology to FS.

Screening and prevention

With new research and the associated understanding of the complex pathophysiology of FS, it is increasingly apparent that the lack of clarity surrounding the diagnosis of FS is, in part, due to a historically oversimplified

approach to this disease that does not consider the heterogeneity of individuals with FS.

As discussed above, FS has been associated with myriad systemic diseases, such as diabetes mellitus, cardiovascular disease and thyroid disorders. Although robust evidence of a causal relationship between these conditions and the development of FS is lacking, there are theories regarding the potential mechanisms that might underlie an increased risk of developing FS. These conditions are associated with chronic low-grade inflammation¹⁹, which has no mechanism of injury and is marked by elevated levels of active pro-inflammatory

cytokines but the absence of the increased neutrophil abundance associated with acute inflammation⁸². The influence of hyperglycaemia on the risk of developing FS is mediated by pro-inflammatory cytokines, which are elevated in the capsule and synovium of patients with FS⁸³. Raised levels of serum cholesterol and pro-inflammatory lipoproteins have also been detected in FS and are risk factors for cardiovascular disorders⁶⁴. Thyroid-stimulating hormone levels also seem to be correlated with the severity of FS¹⁵.

Routine haematological analyses and blood biochemical tests to assess for the presence of inflammatory or metabolic markers are not routinely performed in patients with FS. Although these markers have been shown to be risk factors, their prevalence across the FS population and the impact they may have on disease trajectory and their relation to causal mechanisms remains unknown.

A process that has received little attention to date is the role of chronic or persistent pain. Chronic pain is now viewed as a long-term condition in its own right and has been identified as a global health priority^{46,84}. Central pain mechanisms are known to be present in long-standing shoulder pain and could potentially play a greater role in FS than previously considered^{85,86}. Chronic pain could be compounded by low self-efficacy, pain perceptions and health behaviours such as fear avoidance and kinesiophobia, which can be associated with poor outcomes⁸⁷.

Individuals with traits of anxiety and depression might be at higher risk of a longer duration of symptoms and a poorer prognosis⁸⁸. The independent FS risk factors smoking and obesity have the potential to further exacerbate levels of disability, as their presence, along with sleep deprivation, lower pain thresholds^{89–93}.

Individuals with recalcitrant symptoms in whom traditional, mechanically driven treatments have been unsuccessful often require multispecialty, multimodal input to address the complex physical, emotional and social dimensions that are the consequences of chronic pain conditions. Like screening for existing co-morbidities, validated screening measures for dimensions such as fear avoidance beliefs, pain self-efficacy, sleep disturbance and mood are not routinely used in this cohort of patients^{94–97}. Further research in this area is needed to determine whether such screening tools would be of value when determining individual patient treatments and likely outcomes.

Management

The pathogenesis of FS remains incompletely understood. It is therefore unsurprising that well-defined, evidence-based management guidelines are lacking. In general, a patient with FS can seek non-surgical treatments, such as physiotherapy, medications and corticosteroid injections (CSIs), or more invasive options, such as surgical interventions. Whether disease duration can be influenced by treatment, and the efficacy of each intervention, is unclear, as the evidence for most interventions is mixed³³. Therefore, current treatment of FS focuses primarily on symptom reduction; that is, pain relief and restoring mobility and function.

Non-operative management

There is consensus that non-operative management is the initial treatment of choice for FS⁹⁸. Many non-operative management strategies have been suggested for use in patients with FS. One of the reasons for this is that patients present with a wide array of symptoms and varied levels of disability, which may relate to disease stage. Consequently, it is suggested that a treatment intervention suitable for the disease stage and pain level of the patient be adopted, and there is growing evidence for the value of this approach^{99,100}. In addition, as patients with FS often have high pain levels and functional limitation in combination with a long duration of symptoms, they are often motivated to try every possible intervention that might help them. As symptoms may improve with time in a large proportion of those with FS, it is easy to consider the intervention as the reason for improvement, when in fact this may not be the case.

Patient education. Informing the patient about FS and discussing the natural history is one of the most important initial interventions. The mysterious and uncertain nature of FS can be worrisome and perplexing. Good advice and education reduces patient anxiety and results in subjective improvement of symptoms¹⁰¹; therefore, clearly explaining the evidence-based knowledge of FS natural history, such as expected duration, can have substantial effects on pain and function. It is important to inform patients of the options available to manage FS themselves and to give them simple and clear strategies to modify their occupational or recreational activities as required. It is therefore paramount that all health-care providers provide the same message to reduce confusion, contradiction and negative stress factors. Another important factor in patient education is noting the response to interventions or activity, which differs for each stage; for example, in early FS, no increase in pain and inflammation should be allowed, whereas in the middle and late stages, 24 h of pain increase could be allowed¹⁰².

Physiotherapy. Physiotherapy provides accelerated pain relief¹⁰³ and/or improvement in ROM^{33,103–105} compared with no treatment. However, these improvements are mostly short-term, without a demonstrated reduction in disease duration. It is suggested that the level of irritability of the patient be used to define the appropriate intensity of the chosen management strategy^{102,106,107}. Irritability levels are mainly based on the intensity of pain. For example, in patients with high irritability (pain level at least 7 out of 10), the intervention should be at an intensity that does not induce extra pain, while in patients with moderate irritability (pain level 4–6 out of 10) the intervention will increase in duration and intensity, and in patients with low irritability (pain <3 out of 10) increased duration stretches will be possible, with allowance for some pain or discomfort¹⁰⁸.

Several mobilization and stretching techniques (for example, four-direction shoulder stretching¹⁰⁹ and inferior capsular stretching¹¹⁰) are effective in early and late stages of FS for pain relief^{111,112} and can be

recommended for increasing ROM and function^{102,106}. One of the proposed mechanisms that might explain pain reduction in patients with FS involves the sensory input that activates the endogenous pain inhibitory systems¹¹³. Further study is clearly warranted to determine if endogenous pain inhibitory systems are indeed involved in manual therapeutic interventions around the shoulder. However, in patients with FS who are in their first high irritability stage, the use of passive mobilization or capsular stretching can be counterproductive and can even increase the inflammatory response¹¹⁴. However, a study comparing a combination of manual mobilizations and shoulder exercises to a glucocorticoid injection found that the physiotherapeutic combination probably results in less improvement in the short term but a similar number of adverse events¹¹⁵, although no clinically important differences were noted at 6 and 12 months. Other mobilization techniques, such as Codman's pendulum exercises (passive mobilization of the shoulder while bent over), do not result in a substantial difference in pain or ROM¹¹⁶ compared with other techniques. Unfortunately, there is insufficient evidence to quantify the ideal frequency of mobilization. The intensity of stretching exercises should be determined by the patient's irritability level, as stretching beyond painful limits in a highly irritable patient results in poorer outcomes^{102,106}. In addition to a patient's irritability level, the total end range time (TERT) can be used to report the dose applied to the patient and evaluate progression¹¹⁷. TERT is the total amount of time that the joint is positioned at its end range and is proportional to the increase in passive ROM¹¹⁸. The importance of the right treatment intensity is highlighted again by a prospective study that compared intensive passive stretching and manual mobilization to supportive therapy and exercises within the pain limits, which demonstrated better shoulder function in the supportive group at the end of the 2-year follow-up period¹¹⁹. However, currently there is little evidence to support joint mobilizations over other non-operative interventions¹⁰⁶. As such, the exact effects of exercises, the extent to which they are effective, and the format of exercise therapy that is the most effective are uncertain¹⁰⁵. Preliminary evidence shows that supervised exercise therapy is more effective than unsupervised exercise therapy at home¹²⁰.

Resistance-based exercise may also have an important role in patients with FS, although this approach has been poorly researched. The addition of strengthening exercises to a multimodal programme with mobilization and electrostimulation seems to result in improvements in pain, ROM, function and muscle strength^{121,122}. These improvements were not seen with the addition of scapulothoracic exercises, mobilization and electromagnetic therapy to a similar multimodal programme^{123–125}.

The role of ESWT has been investigated in the treatment of FS. In a randomized, double-blind, placebo-controlled trial comparing radial ESWT to placebo shockwave therapy in 106 participants¹²⁶, substantial improvement in function, pain and ROM occurred in the group who received shockwave. In a trial in patients with primary FS¹²⁷, focused ESWT produced superior pain

outcomes than oral prednisolone. A systematic review of 20 randomized controlled trials found some evidence in favour of ESWT for reduction of pain in FS, although the authors of the review highlighted issues around the quality of evidence and were unable to perform a meta-analysis. For now, definitive conclusions about the efficacy of ESWT as an adjunct to treatment in FS cannot be drawn¹²⁸.

Other physiotherapy modalities, such as cold, heat, electrical modalities such as transcutaneous nerve stimulation, pulsed electromagnetic field therapy and low-level laser therapy, have been suggested to have positive effects on pain in patients with FS. However, as these modalities are typically applied as adjunctive interventions, the individual effect of each technique on the natural course of FS is difficult to define. Consequently, there is only weak evidence in favour of techniques such as shockwave therapy, shortwave diathermy, pulsed electromagnetic field therapy, low-level laser therapy, therapeutic ultrasound and electrical stimulation in reducing pain and improving shoulder ROM in patients with FS^{106,129}.

Mirror therapy is a promising mode of exercise therapy that seems to be effective in the treatment of FS. This approach aims to restore the congruence between motor output and sensory output¹³⁰ and has been beneficial in patients with FS for improving pain, function, ROM in flexion and abduction and general health, although further research is needed¹³¹.

Besides exercises that specifically target the shoulder, general physical activity is recommended for general health, well-being¹⁰², improving mood and sleep¹³², and the prevention of depression¹³². Physical activity can help to reduce or reverse the effects of a sedentary lifestyle, which is often associated with an increase in chronic low-grade inflammation and the development of insulin resistance¹³³.

Pharmacotherapy. Common medications for patients with FS include paracetamol or acetaminophen, NSAIDs and corticosteroids. The evidence for the use of paracetamol in patients with FS is limited, but it may be useful when there are contraindications to the use of other medications^{134–136}. Paracetamol inhibits cyclooxygenase and is active both peripherally and centrally. FS has been shown to be an inflammatory process followed by fibrosis, and therefore theoretically NSAIDs should be more effective in the early inflammatory stage than in the later fibrotic stage¹². However, this has not yet been shown clinically. NSAIDs might be used for pain relief, but do not have an effect on ROM³³. In addition, NSAIDs influence the serotonergic system, which may provide some benefit in modulating perceived pain in addition to their direct anti-inflammatory effect¹³⁴. Oral corticosteroids provide quicker pain relief compared with placebo, but this effect has not been seen in the long term, and in some cases this treatment can exacerbate symptoms owing to rebound pain after their discontinuation^{33,99,111,112}.

Intra-articular CSIs are recommended in the inflammatory or early stages of FS, before the emergence of capsular contraction, to provide pain relief and reduce inflammation^{137–140}. Histologically, intra-articular

CSIs have been associated with decreased fibrosis proliferation¹⁴⁰. CSIs are more effective than placebo, but do not change long-term (6-month and 12-month) outcomes¹⁴¹. CSIs are more effective than physical therapy in decreasing pain in the early stages of FS^{33,99,111,112,142}, but the difference is minimal in the long term¹⁰³. CSI alone has no effect on ROM but a combination of CSI and physiotherapy improves ROM¹¹¹. In general, CSI in early stage (stage I or II) FS results in greater improvement in pain and function than in late (stage III or IV) FS¹⁴³. Although the risks are low, there are potential complications with the use of intra-articular CSI, including avascular necrosis, infection, muscle complaints and pain increase^{144–146}. Intra-articular CSI can also lead to a transient increase in serum glucose, which may be relevant in patients with FS who have diabetes.

Alternative interventions. There are limited and mixed data for several other interventions, including sodium hyaluronate injection^{147,148}, suprascapular nerve block^{149,150}, collagenase treatment¹⁵¹, botulinum toxin¹⁵² and hydrodilatation^{153,154} for use in FS, with the most supporting evidence for botulinum toxin and hydrodilatation.

Hydrodilatation therapy refers to intra-articular injection of a large volume of sterile saline with or without corticosteroid to distend the capsule. Hydrodilatation therapy is a promising intervention that has gained popularity over the past 10 years^{155–157}. A meta-analysis found that both CSI and hydrodilatation with corticosteroids provide superior short-term pain relief, ROM improvement and function compared with placebo, with ROM improvements persisting to beyond 24 months¹⁵⁷. Hydrodilatation with corticosteroids was found to have a greater benefit than CSI¹⁵⁸.

Following its successful use in Dupuytren disease, collagenase clostridium histolyticum (CCH) has also been utilized to treat FS. CCH is typically given as a series of three injections over 6 weeks. A randomized study showed improvement in subjective function with CCH but no notable increase in ROM compared with placebo¹⁵⁹. Another study found a greater improvement in ROM at 3 months with CCH than with exercise therapy alone¹⁵¹. Histological examination of capsular tissue

in a rat model of FS revealed less fibrosis with CCH injection than with CSI or saline¹⁶⁰. These data support a potential role for CCH in the management of FS.

In conclusion, while many interventions have been described, the most reliable benefits are from steroid injection and NSAIDs in stage I FS, physiotherapy in stage II–III FS, and advancement of physiotherapy to mirror or resistance exercises in stage III FS (TABLE 1).

Operative management

After ruling out other causes of pain and stiffness of the shoulder, the patient should be informed that the natural history of the condition is eventual resolution in most patients. However, symptoms and disability persist in some patients, and surgical management may provide a faster, more complete recovery. The aim of surgical approaches in FS is to release the fibrous, thickened and tightened glenohumeral joint capsule and associated contracted ligaments to improve ROM of the glenohumeral joint, and to decrease pain.

MUA. The aim of MUA is to stretch the shoulder joint capsule and thereby improve ROM. In an anaesthetized shoulder, the procedure involves applying a passive stretch to the glenohumeral joint, in all shoulder ROM directions. There are conflicting opinions as to the ideal time to perform MUA in patients with idiopathic FS, from as soon as FS is diagnosed^{161,162} to up to 12 months after failed non-operative treatment^{1,100,163}. Several studies have cited improved outcomes from MUA in more than 80% of patients^{112,162,164–166}.

ACR with or without MUA manipulation. ACR involves cutting and removing the thickened, swollen, inflamed abnormal capsule under direct arthroscopic control. ACR is a safe and effective modality in treating FS^{163,164,167–171} and may offer distinct advantages when compared with other methods of treatment. For example, direct visualization of the affected joint allows diagnostic confirmation and enables additional pathology to be ruled out. The effectiveness of ACR has been demonstrated in multiple studies, with a dramatic reduction in pain scores, increased ROM as well as overall increased shoulder function^{169–173}.

Comparison of ACR and MUA. UK FROST¹⁷⁴ is the largest multicentre randomized trial in FS, which compared early structured physiotherapy¹¹⁶, MUA and ACR. Early structured physiotherapy and post-procedural physiotherapy programmes were standardized at 12 sessions over 12 weeks. At the 12-month primary end point, most participants had improved to near full function, as determined by the Oxford Shoulder Score (43 out of 48), a quality of life outcome score. Oxford Shoulder Scores were significantly higher in the ACR group than in the MUA and early structured physiotherapy groups ($P < 0.01$), and were higher in the MUA group than in the early structured physiotherapy group. Economic analysis in the UK FROST study¹⁷⁴ showed that MUA is more costly (£276) and ACR is substantially more costly (£1,734) than early structured physiotherapy. All three treatments led to substantial patient recovery,

Table 1 | Treatment approaches for frozen shoulder based on stage of the condition

Stage	Characteristics	Treatment approaches		
		Pharmacological	Physical	Other adjuncts
I	Inflammation	NSAIDs CSI	Home exercises	Patient education Hydrodilatation TENS
II	Freezing and frozen	NSAIDs	Physiotherapy: mobilization	Patient education Hydrodilatation Shockwave therapy
III	Thawing	NA	Physiotherapy: resistance-based	Surgical management if symptoms do not dissipate

CSI, corticosteroid injection; NA, not applicable; TENS, transcutaneous electrical nerve stimulation.

with no clear superiority for any approach. ACR resulted in patients requiring the least amount of further treatment, but was the most expensive, and was associated with higher risks, suggesting it should only be utilized when less-costly and less-invasive interventions fail. Early structured physiotherapy was accessed faster, but more patients required further treatment.

In summary, the surgical options of MUA and ACR may provide an earlier, potentially more complete resolution of pain and restoration of ROM and function, although these interventions should be considered only after non-operative management approaches have failed.

Quality of life

FS results in significant functional disability and reduction in quality of life, as shown using various questionnaires and scores, such as the visual analogue scale, disabilities of the arm, shoulder and hand (DASH) score, the 36-item Short-Form (SF-36) health survey, and the Hamilton depression rating scale and anxiety scores⁸⁷. It is not clear what factors predict the severity of pain and disability as well as quality of life in patients with FS¹⁷⁵. The prolonged disease course in FS results in greatly impaired sleep and everyday activities and, therefore, markedly affects the physical, psychological and social quality of life of patients^{175–177}. FS has been linked to anxiety and depression¹⁷⁷. Co-morbidities are associated with increased disability and reduced quality of life in these patients but not with the severity of pain. Psychiatric disorders can also affect pain, disability and quality of life as well as patients' characteristic and objective symptoms¹⁷⁸, but the effect of these parameters on FS requires further study.

The patient's perspective and experience has been largely overlooked in FS research. This is startling, particularly when considering the vast numbers affected by this condition and the subsequent health-care cost, and the implications of long-term symptoms and reduced quality of life as a result of FS. A study¹⁰¹ exploring patients' perceptions of FS treatment highlighted the severe pain and loss of function that impacted their daily life, alongside sleep disturbance and inability to perform work duties. Delay in diagnosis was a cause of frustration and worry for the patients interviewed, as the severity of pain often led patients to suspect that there might be a more sinister cause of their pain. Patients also highlighted a lack of a definitive diagnosis alongside unclear pathways for management of their condition and emphasized a mismatch between their perception of the impact of FS and that of the clinician. Although only involving a small number of patients, this study stresses the need for a better understanding of FS, for both clinicians and patients. To improve a patient's experience with FS, a prompt diagnosis, a clear understanding of the treatment options available and an explanation of the course of this painful condition are priorities. Aligning treatment goals with those of patients suffering with FS should underpin clinicians' interaction with patients who present with FS and future research into this condition. Clearly, the patient's voice has not been heard enough in studies thus far.

Outlook

Research in recent decades has improved our understanding of known risk factors and disease progression, and, importantly, insights into the basic mechanisms driving the disease process, with the potential for new therapeutic targets. Despite affecting 5% of the world's population¹⁶⁴, research into FS lags behind that of other musculoskeletal conditions, and integration of new findings into a comprehensive treatment strategy that can be applied across the spectrum of disease (from early-stage through to late-stage disease) and medical practitioners (physiotherapists, primary care physicians and surgeons) remains elusive. Of note, emerging basic science research needs to be assimilated into clinical practice to provide clinicians with a picture of the principal pathophysiological processes involved in FS.

Physiotherapy advances

The component of physiotherapy that includes mobilization techniques beyond the threshold of pain in early disease can be detrimental to patient engagement and is explained by the unique mechanosensitive properties of fibroblasts and the fact that the inflammatory response makes fibroblasts more sensitive to progressive mechanical stress¹¹⁹. However, progressive stretching exercises up to tolerable pain levels results in an increase in the MMP to TIMP ratio, thus favouring collagen remodelling, and importantly is superior to supervised neglect¹⁷⁹. Therefore, some mechanical stress is advantageous in promoting remodelling of the ECM, especially in the later stage of the condition. Thus, further research is required on the role of precision 'tailored' physiotherapy guidelines for the treatment of FS.

Translational advances

Novel bench to bedside treatment strategies have been suggested for intervening in the inflammation–fibrosis cascade in different ways. Given the dominant role of the TGF β pathway in FS, gene silencing (with small interfering RNAs) was utilized to knockdown *Smad4* (a central mediator of TGF β signalling) in a rat model of FS induced by immobilization¹⁸⁰. Suppression of the TGF β pathway impaired the inflammatory response and myofibroblast differentiation and resulted in better shoulder ROM and an increased joint volume in a rodent model of FS compared with control rats. In a placebo-controlled, double-blind, randomized trial, the thyroid hormone calcitonin (delivered by nasal spray) was moderately efficacious in improving pain and functional outcomes in FS⁶⁸. Another study found an association between expression of alarmins (such as IL-33, IL-17A and HMGB1) and pain levels⁴⁵, highlighting a potential role for anti-cytokine therapies in treating FS; however, additional preclinical work is required before progressing towards potential first-in-human trials in FS.

Clinical advances

Clinically, knowledge about pain management and the association between pain and other psychological disorders, such as depression and anxiety, is expanding. In addition, the central element of night pain in FS has a major impact on patients' overall well-being

owing to interruption of sleep, and the emotional and societal implications of these factors are not well understood. These issues may play an important role in the management of FS in the future as these associations are clarified.

The lack of well-conducted prospective longitudinal studies to adequately investigate prognostic risk factors for FS is a barrier to furthering our understanding of this pathology. Although none of the risk factors discussed earlier are known to have a direct causative role, their high prevalence in the FS population indicates that reducing or improving them would be useful. Therefore, clear, simple and actionable health promotion advice regarding smoking cessation, physical activity, stress and sleep levels, diet and weight management is recommended. Even slight increases in physical activity and exercise can substantially reduce the relative risks of both morbidity and mortality associated with many of the proposed risk factors for FS¹⁸¹. Increasing walking time to just 2 h a week significantly reduces the risk of cardiovascular disease in individuals with diabetes¹⁸² and both aerobic and resistance-based exercise demonstrably reduces morbidity risk^{183–185}. In the near future, ‘frozen shoulder’ could be considered an umbrella term for emerging subgroups of this pathology, each with its own aetiology, disease progression, prognosis and management strategies. While novel therapeutic modalities to treat FS are evolving, there should also perhaps be a concomitant focus on preventing the important and

avoidable risk factors involved. Population health messages delivered consistently by health-care professionals across all sectors should be considered core tenets within musculoskeletal care. This should include an honest and open, yet compassionate, discussion and acknowledgment that it may take weeks, months or years for the benefits of lifestyle changes to make any demonstrable impact on patient outcomes¹⁸⁶.

Clinical trials in FS remain challenging, with inconsistencies in outcome measures, heterogeneity of patient stage at recruitment and the requirement for prolonged follow-up. Although advances have been made towards a consensus in terms of a core set of outcome domains for use in trials in shoulder disorders¹⁸⁷, several important issues need to be addressed, including heterogeneity in study design, stage-specific or patient-specific treatment protocols, and how we classify response to any treatment regimen — specifically those altering specific physiotherapy regimes. Further research is now required to link the genetic, epigenetic, environmental and therapeutic factors together so that curative or preventive therapies for FS can be obtained. These findings should give impetus to the development of new diagnostic techniques, evidence-based screening methods and more targeted personalized interventions, which underscore the need for a multidisciplinary approach to the management of FS.

Published online: 08 September 2022

- Neviaser, R. J. & Neviaser, T. J. The frozen shoulder. Diagnosis and management. *Clin. Orthop. Relat. Res.* **223**, 59–64 (1987).
Classic original article describing frozen shoulder and treatment options.
- Kim, D. H. et al. Is frozen shoulder completely resolved at 2 years after the onset of disease? *J. Orthop. Sci.* **25**, 224–228 (2020).
- Shaffer, B., Tibone, J. E. & Kerlan, R. K. Frozen shoulder. A long-term follow-up. *J. Bone Joint Surg. Am.* **74**, 738–746 (1992).
- Hand, C., Clipsham, K., Rees, J. L. & Carr, A. J. Long-term outcome of frozen shoulder. *J. Shoulder Elb. Surg.* **17**, 231–236 (2008).
Key article looking at the longer term outcomes of frozen shoulder.
- Walker-Bone, K., Palmer, K. T., Reading, I., Coggon, D. & Cooper, C. Prevalence and impact of musculoskeletal disorders of the upper limb in the general population. *Arthritis Rheum.* **51**, 642–651 (2004).
- Sarasua, S. M., Floyd, S., Bridges, W. C. & Pill, S. G. The epidemiology and etiology of adhesive capsulitis in the US Medicare population. *BMC Musculoskelet. Disord.* **22**, 828 (2021).
- Kingston, K., Curry, E. J., Galvin, J. W. & Li, X. Shoulder adhesive capsulitis: epidemiology and predictors of surgery. *J. Shoulder Elb. Surg.* **27**, 1437–1443 (2018).
- Rizk, T. E. & Pinals, R. S. Frozen shoulder. *Semin. Arthritis Rheum.* **11**, 440–452 (1982).
- Looney, C. G., Raynor, B. & Lowe, R. Adhesive capsulitis of the hip: a review. *J. Am. Acad. Orthop. Surg.* **21**, 749–755 (2013).
- Cui, Q., Milbrandt, T., Millington, S., Anderson, M. & Hurwitz, S. Treatment of posttraumatic adhesive capsulitis of the ankle: a case series. *Foot Ankle Int.* **26**, 602–606 (2005).
- de la Serna, D., Navarro-Ledesma, S., Alayon, F., Lopez, E. & Pruijboom, L. A comprehensive view of frozen shoulder: a mystery syndrome. *Front. Med.* **8**, 663703 (2021).
- Le, H. V., Lee, S. J., Nazarian, A. & Rodriguez, E. K. Adhesive capsulitis of the shoulder: review of pathophysiology and current clinical treatments. *Shoulder Elb.* **9**, 75–84 (2017).
- Juel, N. G., Brox, J. I., Brunborg, C., Holte, K. B. & Berg, T. J. Very high prevalence of frozen shoulder in patients with type 1 diabetes of ≥ 45 years' duration: the Dialong shoulder study. *Arch. Phys. Med. Rehabil.* **98**, 1551–1559 (2017).
- Alhashimi, R. A. H. Analytical observational study of frozen shoulder among patients with diabetes mellitus. *Joints* **6**, 141–144 (2018).
- Schiefer, M. et al. Prevalence of hypothyroidism in patients with frozen shoulder. *J. Shoulder Elb. Surg.* **26**, 49–55 (2017).
- Wang, J.-Y. et al. Hyperlipidemia is a risk factor of adhesive capsulitis: real-world evidence using the Taiwanese National Health Insurance Research Database. *Orthop. J. Sports Med.* **9**, 2325967120986808 (2021).
- Li, W., Lu, N., Xu, H., Wang, H. & Huang, J. Case control study of risk factors for frozen shoulder in China. *Int. J. Rheum. Dis.* **18**, 508–513 (2015).
- Itoi, E. et al. Shoulder stiffness: current concepts and concerns. *Arthroscopy* **32**, 1402–1414 (2016).
Classic article on general aspects of shoulder stiffness and management options.
- Pietrzak, M. Adhesive capsulitis: an age related symptom of metabolic syndrome and chronic low-grade inflammation? *Med. Hypotheses* **88**, 12–17 (2016).
- Smith, S. P., Devaraj, V. S. & Bunker, T. D. The association between frozen shoulder and Dupuytren's disease. *J. Shoulder Elb. Surg.* **10**, 149–151 (2001).
- Green, H. D. et al. A genome-wide association study identifies 5 loci associated with frozen shoulder and implicates diabetes as a causal risk factor. *PLoS Genet.* **17**, e1009577 (2021).
- Kilian, O. et al. Enhanced alpha1(I) mRNA expression in frozen shoulder and Dupuytren tissue. *Eur. J. Med. Res.* **12**, 585–590 (2007).
- Thompson, W. A. & Kopell, H. P. Peripheral entrapment neuropathies of the upper extremity. *N. Engl. J. Med.* **260**, 1261–1265 (1959).
- Giordano, L., Sarandria, D., Fabiano, B., Del Carro, U. & Bussi, M. Shoulder function after selective and superselective neck dissections: clinical and functional outcomes. *Acta Otorhinolaryngol. Ital.* **32**, 376–379 (2012).
- Tanishima, T. & Yoshimasu, N. Development and prevention of frozen shoulder after acute aneurysm surgery. *Surg. Neurol.* **48**, 19–22 (1997).
- Papalia, R. et al. Frozen shoulder or shoulder stiffness from Parkinson disease? *Musculoskelet. Surg.* **103**, 115–119 (2019).
- Wilson, R. D. & Chae, J. Hemiplegic shoulder pain. *Phys. Med. Rehabil. Clin. N. Am.* **26**, 641–655 (2015).
- Neviaser, A. S. & Neviaser, R. J. Adhesive capsulitis of the shoulder. *J. Am. Acad. Orthop. Surg.* **19**, 536–542 (2011).
- Ryu, J. D. et al. Expression of vascular endothelial growth factor and angiogenesis in the diabetic frozen shoulder. *J. Shoulder Elb. Surg.* **15**, 679–685 (2006).
- Xu, Y., Bonar, F. & Murrell, G. A. Enhanced expression of neuronal proteins in idiopathic frozen shoulder. *J. Shoulder Elb. Surg.* **21**, 1391–1397 (2012).
- Lho, Y. M. et al. Inflammatory cytokines are overexpressed in the subacromial bursa of frozen shoulder. *J. Shoulder Elb. Surg.* **22**, 666–672 (2013).
- Ryan, V., Brown, H., Minns Lowe, C. J. & Lewis, J. S. The pathophysiology associated with primary (idiopathic) frozen shoulder: a systematic review. *BMC Musculoskelet. Disord.* **17**, 340 (2016).
- Neviaser, A. S. & Hannafin, J. A. Adhesive capsulitis: a review of current treatment. *Am. J. Sports Med.* **38**, 2346–2356 (2010).
- Hand, G. C. R., Athanasou, N. A., Matthews, T. & Carr, A. J. The pathology of frozen shoulder. *J. Bone Joint Surg. Br.* **89**, 928–932 (2007).
Important basic science study looking at the pathophysiology of frozen shoulder.
- Kanbe, K., Inoue, K., Inoue, Y. & Chen, Q. Inducement of mitogen-activated protein kinases in frozen shoulders. *J. Orthop. Sci.* **14**, 56–61 (2009).
- Dakin, S. G. et al. Tissue inflammation signatures point towards resolution in adhesive capsulitis. *Rheumatology* **58**, 1109–1111 (2019).
- Akbar, M. et al. Translational targeting of inflammation and fibrosis in frozen shoulder: molecular dissection of the T cell/IL-17A axis. *Proc. Natl Acad. Sci. USA* **118**, e2102715118 (2021).
- Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. *Nat. Med.* **26**, 1295–1306 (2020).
- Rodeo, S. A., Hannafin, J. A., Tom, J., Warren, R. F. & Wickiewicz, T. L. Immunolocalization of cytokines

- and their receptors in adhesive capsulitis of the shoulder. *J. Orthop. Res.* **15**, 427–436 (1997). **First description of dysregulated cytokines and inflammation in frozen shoulder.**
40. Kraal, T. et al. The puzzling pathophysiology of frozen shoulders—a scoping review. *J. Exp. Orthop.* **7**, 91 (2020).
 41. Bunker, T. D., Reilly, J., Baird, K. S. & Hamblen, D. L. Expression of growth factors, cytokines and matrix metalloproteinases in frozen shoulder. *J. Bone Joint Surg. Br.* **82**, 768–773 (2000).
 42. Akbar, M. et al. Fibroblast activation and inflammation in frozen shoulder. *PLoS ONE* **14**, e0215301 (2019).
 43. Millar, N. L. et al. IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy. *Sci. Rep.* **6**, 27149 (2016).
 44. Millar, N. L. et al. Tendinopathy. *Nat. Rev. Dis. Primers* **7**, 82 (2021).
 45. Cher, J. Z. B. et al. Alarmins in frozen shoulder: a molecular association between inflammation and pain. *Am. J. Sports Med.* **46**, 671–678 (2018). **Article discussing alarmins and clinical correlation of inflammation and pain.**
 46. Moayedi, M. et al. Contribution of chronic pain and neuroticism to abnormal forebrain gray matter in patients with temporomandibular disorder. *Neuroimage* **55**, 277–286 (2011).
 47. Millar, N. L., Murrell, G. A. & McInnes, I. B. Alarmins in tendinopathy: unravelling new mechanisms in a common disease. *Rheumatology* **52**, 769–779 (2013).
 48. Hwang, K. R. et al. Advanced glycation end products in idiopathic frozen shoulders. *J. Shoulder Elb. Surg.* **25**, 981–988 (2016).
 49. Hagiwara, Y. et al. Coexistence of fibrotic and chondrogenic process in the capsule of idiopathic frozen shoulders. *Osteoarthritis Cartilage* **20**, 214–219 (2012).
 50. Ha, E., Lho, Y.-M., Seo, H.-J. & Cho, C.-H. Melatonin plays a role as a mediator of nocturnal pain in patients with shoulder disorders. *J. Bone Joint Surg. Am.* **96**, e108 (2014).
 51. Cho, C.-H., Song, K.-S., Kim, B.-S., Kim, D. H. & Lho, Y.-M. Biological aspect of pathophysiology for frozen shoulder. *Biomed. Res. Int.* **2018**, 7274517 (2018).
 52. Hutchinson, J. W., Tierney, G. M., Parsons, S. L. & Davis, T. R. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. *J. Bone Joint Surg. Br.* **80**, 907–908 (1998).
 53. Frangiannidis, N. Transforming growth factor- β in tissue fibrosis. *J. Exp. Med.* **217**, e20190103 (2020).
 54. Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M. C. & Ten Dijke, P. TGF- β -induced endothelial-mesenchymal transition in fibrotic diseases. *Int. J. Mol. Sci.* **18**, 2157 (2017).
 55. Caja, L. et al. TGF- β and the tissue microenvironment: relevance in fibrosis and cancer. *Int. J. Mol. Sci.* **19**, 1294 (2018).
 56. Crowe, L. A. N. et al. Stromal “activation” markers do not confer pathogenic activity in tendinopathy. *Transl. Sports Med.* **4**, 268–279 (2021).
 57. Garcilazo, C., Cavallasca, J. A. & Musuruana, J. L. Shoulder manifestations of diabetes mellitus. *Curr. Diabetes Rev.* **6**, 334–340 (2010).
 58. Dyer, B. P., Burton, C., Rathod-Mistry, T., Blagojevic-Bucknall, M. & van der Windt, D. A. Diabetes as a prognostic factor in frozen shoulder: a systematic review. *Arch. Rehabil. Res. Clin. Transl* **3**, 100141 (2021).
 59. Hsu, C.-L. & Sheu, W. H.-H. Diabetes and shoulder disorders. *J. Diabetes Investig.* **7**, 649–651 (2016).
 60. Perkins, T. N. & Oury T. D. The perplexing role of RAGE in pulmonary fibrosis: causality or casualty? *Ther. Adv. Respir. Dis.* **15**, 175346662111016071 (2021).
 61. Sabbatinelli, J. et al. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study. *Cardiovasc. Diabetol.* **21**, 95 (2022).
 62. Taqueti, V. R. & Ridker, P. M. Lipid-lowering and anti-inflammatory benefits of statin therapy: more than meets the plaque. *Circ. Cardiovasc. Imaging* **10**, e006676 (2017).
 63. Jeong, C. et al. Exploring the in vivo anti-inflammatory actions of simvastatin-loaded porous microspheres on inflamed tenocytes in a collagenase-induced animal model of achilles tendinitis. *Int. J. Mol. Sci.* **19**, 820 (2018).
 64. Sung, C. M., Jung, T. S. & Park, H. B. Are serum lipids involved in primary frozen shoulder? A case-control study. *J. Bone Joint Surg. Am.* **96**, 1828–1833 (2014).
 65. Struyf, F., Mertens, M. G. & Navarro-Ledesma, S. Causes of shoulder dysfunction in diabetic patients: a review of literature. *Int. J. Environ. Res. Public Health* **19**, 6228 (2022).
 66. Chen, J. et al. Pathological changes of frozen shoulder in rat model and the therapeutic effect of PPAR- γ agonist. *J. Orthop. Res.* **39**, 891–901 (2021).
 67. Huang, S.-W. et al. Hyperthyroidism is a risk factor for developing adhesive capsulitis of the shoulder: a nationwide longitudinal population-based study. *Sci. Rep.* **4**, 4183 (2014).
 68. Rouhani, A. et al. Calcitonin effects on shoulder adhesive capsulitis. *Eur. J. Orthop. Surg. Traumatol.* **26**, 575–580 (2016).
 69. Hamdy, R. C. & Daley, D. N. Oral calcitonin. *Int. J. Womens Health* **4**, 471–479 (2012).
 70. Yang, R. et al. Investigation of salmon calcitonin in regulating fibrosis-related molecule production and cell-substrate adhesion in frozen shoulder synovial/capsular fibroblasts. *J. Orthop. Res.* **38**, 1375–1385 (2020).
 71. Hollmann, L., Halaki, M., Kamper, S. J., Haber, M. & Ginn, K. A. Does muscle guarding play a role in range of motion loss in patients with frozen shoulder? *Musculoskelet. Sci. Pract.* **37**, 64–68 (2018).
 72. Walmsley, S., Rivett, D. A. & Osmotherly, P. G. Adhesive capsulitis: establishing consensus on clinical identifiers for stage 1 using the DELPHI technique. *Phys. Ther.* **89**, 906–917 (2009).
 73. Sharma, S. P., Bærheim, A. & Kvåle, A. Passive range of motion in patients with adhesive shoulder capsulitis, an intertester reliability study over eight weeks. *BMC Musculoskelet. Disord.* **16**, 37 (2015).
 74. Lee, S. H. et al. Measurement of shoulder range of motion in patients with adhesive capsulitis using a Kinect. *PLoS ONE* **10**, e0129398 (2015).
 75. De Baets, L., Matheve, T., Traxler, J., Vlaeyen, J. & Timmermans, A. Pain-related beliefs are associated with arm function in persons with frozen shoulder. *Shoulder Elb.* **12**, 432–440 (2020).
 76. Quan, G. M., Carr, D., Schlicht, S., Powell, G. & Choong, P. F. Lessons learnt from the painful shoulder; a case series of malignant shoulder girdle tumours misdiagnosed as frozen shoulder. *Int. Semin. Surg. Oncol.* **2**, 2 (2005).
 77. Rangan, A. et al. Frozen shoulder. *Shoulder Elb.* **7**, 299–307 (2015).
 78. Roberts, S. et al. Routine X-rays for suspected frozen shoulder offer little over diagnosis based on history and clinical examination alone. *Musculoskelet. Care* **17**, 288–292 (2019).
 79. Choi, Y. H. & Kim, D. H. Correlations between clinical features and MRI findings in early adhesive capsulitis of the shoulder: a retrospective observational study. *BMC Musculoskelet. Disord.* **21**, 542 (2020).
 80. Do, J. G., Hwang, J. T., Yoon, K. J. & Lee, Y. T. Correlation of ultrasound findings with clinical stages and impairment in adhesive capsulitis of the shoulder. *Orthop. J. Sports Med.* **9**, 23259671211003675 (2021).
 81. Lewis, J. Frozen shoulder contracture syndrome—etiology, diagnosis and management. *Man. Ther.* **20**, 2–9 (2015).
 82. Minihane, A. M. et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. *Br. J. Nutr.* **114**, 999–1012 (2015).
 83. Austin, D. C., Gans, I., Park, M. J., Carey, J. L. & Kelly, J. D. T. The association of metabolic syndrome markers with adhesive capsulitis. *J. Shoulder Elb. Surg.* **23**, 1043–1051 (2014).
 84. Treede, R. D. et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). *Pain* **160**, 19–27 (2019).
 85. Sanchis, M. N., Lluch, E., Nijs, J., Struyf, F. & Kangasperko, M. The role of central sensitization in shoulder pain: a systematic literature review. *Semin. Arthritis Rheum.* **44**, 710–716 (2015). **Important article looking at the role of central pain in the shoulder.**
 86. Noten, S. et al. Central pain processing in patients with shoulder pain: a review of the literature. *Pain Pract.* **17**, 267–280 (2017).
 87. Bagheri, F., Ebrahimzadeh, M. H., Moradi, A. & Bidgoli, H. Factors associated with pain, disability and quality of life in patients suffering from frozen shoulder. *Arch. Bone Jt Surg.* **4**, 243–247 (2016).
 88. Chiamonte, R., Bonfiglio, M. & Chisari, S. A significant relationship between personality traits and adhesive capsulitis. *Rev. Assoc. Med. Bras.* **66**, 166–173 (2020).
 89. John, U. et al. Tobacco smoking in relation to pain in a national general population survey. *Prev. Med.* **43**, 477–481 (2006).
 90. Guneli, E., Gumustekin, M. & Ates, M. Possible involvement of ghrelin on pain threshold in obesity. *Med. Hypotheses* **74**, 452–454 (2010).
 91. Pisinger, C. et al. The association between active and passive smoking and frequent pain in a general population. *Eur. J. Pain* **15**, 77–83 (2011).
 92. Kundermann, B., Krieg, J. C., Schreiber, W. & Lautenbacher, S. The effect of sleep deprivation on pain. *Pain Res. Manag.* **9**, 25–32 (2004).
 93. Schuh-Hofer, S. et al. One night of total sleep deprivation promotes a state of generalized hyperalgesia: a surrogate pain model to study the relationship of insomnia and pain. *Pain* **154**, 1613–1621 (2013).
 94. van Noorden, M. S. et al. Pre-adult versus adult onset major depressive disorder in a naturalistic patient sample: the Leiden Routine Outcome Monitoring Study. *Psychol. Med.* **41**, 1407–1417 (2011).
 95. Nicholas, M. K. & Blyth, F. M. Are self-management strategies effective in chronic pain treatment? *Pain Manag.* **6**, 75–88 (2016).
 96. Bastien, C. H., Vallieres, A. & Morin, C. M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med.* **2**, 297–307 (2001).
 97. Zigmond, A. S. & Snaith, R. P. The Hospital Anxiety and Depression Scale. *Acta Psychiatr. Scand.* **67**, 361–370 (1983).
 98. Yip, M. et al. Treatment of adhesive capsulitis of the shoulder: a critical analysis review. *JBJS Rev.* **6**, e5 (2018).
 99. Cho, C. H., Bae, K. C. & Kim, D. H. Treatment strategy for frozen shoulder. *Clin. Orthop. Surg.* **11**, 249–257 (2019).
 100. Redler, L. H. & Dennis, E. R. Treatment of adhesive capsulitis of the shoulder. *J. Am. Acad. Orthop. Surg.* **27**, e544–e554 (2019).
 101. Jones, S., Hanchard, N., Hamilton, S. & Rangan, A. A qualitative study of patients' perceptions and priorities when living with primary frozen shoulder. *BMJ Open* **3**, e003452 (2013).
 102. Vermeulen, H. M., Schuitemaker, R., Hekman, K. M. C., van der Burg, D. H. & Struyf, F. *De SNN Praktijkrichtlijn Frozen Shoulder voor Fysiotherapeuten* (Schoudernetwerken Nederland, 2017).
 103. Brue, S. et al. Idiopathic adhesive capsulitis of the shoulder: a review. *Knee Surg. Sports Traumatol. Arthrosc.* **15**, 1048–1054 (2007).
 104. Sheridan, M. A. & Hannafin, J. A. Upper extremity: emphasis on frozen shoulder. *Orthop. Clin. North. Am.* **37**, 531–539 (2006).
 105. Hanchard, N. C. A. et al. Evidence-based clinical guidelines for the diagnosis, assessment and physiotherapy management of contracted (frozen) shoulder: quick reference summary. *Physiotherapy* **98**, 117–120 (2012). **Excellent quick reference for management of frozen shoulder for the busy clinician.**
 106. Kelley, M. J. et al. Shoulder pain and mobility deficits: adhesive capsulitis. *J. Orthop. Sports Phys. Ther.* **43**, A1–A31 (2013).
 107. McClure, P. W. & Michener, L. A. Staged approach for rehabilitation classification: shoulder disorders (STAR-shoulder). *Phys. Ther.* **95**, 791–800 (2015).
 108. Duenas, L. et al. A manual therapy and home stretching program in patients with primary frozen shoulder contracture syndrome: a case series. *J. Orthop. Sports Phys. Ther.* **49**, 192–201 (2019). **Article giving key home exercises for frozen shoulder.**
 109. Griggs, S. M., Ahn, A. & Green, A. Idiopathic adhesive capsulitis. A prospective functional outcome study of nonoperative treatment. *J. Bone Joint Surg. Am.* **82**, 1398–1407 (2000).
 110. Paul, A., Rajkumar, J. S., Peter, S. & Lambert, L. Effectiveness of sustained stretching of the inferior capsule in the management of a frozen shoulder. *Clin. Orthop. Relat. Res.* **472**, 2262–2268 (2014).
 111. Favejee, M. M., Huisstede, B. M. & Koes, B. W. Frozen shoulder: the effectiveness of conservative and surgical interventions—systematic review. *Br. J. Sports Med.* **45**, 49–56 (2011).
 112. Georgiannos, D. H., Markopoulos, G., Devetzi, E. & Bisbinas, I. Adhesive capsulitis of the shoulder. Is there consensus regarding the treatment? A comprehensive review. *Open Orthop. J.* **11**, 65–76 (2017).
 113. Yarnitsky, D. Role of endogenous pain modulation in chronic pain mechanisms and treatment. *Pain* **156** (Suppl. 1), S24–S31 (2015).

114. Mertens, M. G. et al. An overview of effective and potential new conservative interventions in patients with frozen shoulder. *Rheumatol. Int.* **42**, 925–936 (2022).
115. Page, M. J. et al. Manual therapy and exercise for adhesive capsulitis (frozen shoulder). *Cochrane Database Syst. Rev.* <https://doi.org/10.1002/14651858.CD011275> (2014).
116. Zavala-Gonzalez, J., Pavez-Baeza, F., Gutierrez-Espinoza, H. & Olguin-Huerta, C. The effectiveness of joint mobilization techniques for range of motion in adult patients with primary adhesive capsulitis of the shoulder: a systematic review and meta-analysis. *Medwave* **18**, e7265 (2018).
117. Kelley, M. J., McClure, P. W. & Leggin, B. G. Frozen shoulder: evidence and a proposed model guiding rehabilitation. *J. Orthop. Sports Phys. Ther.* **39**, 135–148 (2009).
118. Flowers, K. R. & LaStayo, P. Effect of total end range time on improving passive range of motion. *J. Hand Ther.* **7**, 150–157 (1994).
119. Diercks, R. L. & Stevens, M. Gentle thawing of the frozen shoulder: a prospective study of supervised neglect versus intensive physical therapy in seventy-seven patients with frozen shoulder syndrome followed up for two years. *J. Shoulder Elb. Surg.* **13**, 499–502 (2004).
120. Russell, S. et al. A blinded, randomized, controlled trial assessing conservative management strategies for frozen shoulder. *J. Shoulder Elb. Surg.* **23**, 500–507 (2014).
121. Rawat, P., Eapen, C. & Seema, K. P. Effect of rotator cuff strengthening as an adjunct to standard care in subjects with adhesive capsulitis: a randomized controlled trial. *J. Hand Ther.* **30**, 235–241. e8 (2017).
122. Kumar, G., Sudhakar, S., Sudhan, S. & Jyothi, N. Subscapularis muscle spray and stretch technique with conventional physical therapy for the management of adhesive capsulitis. *Biomedicine* **37**, 511–517 (2017).
123. Celik, D. Comparison of the outcomes of two different exercise programs on frozen shoulder. *Acta Orthop. Traumatol. Turc.* **44**, 285–292 (2010).
124. Junaid, M. et al. A comparative study to determine the efficacy of routine physical therapy treatment with and without Kaltenborn mobilization on pain and shoulder mobility in frozen shoulder patients. *Int. J. Physiother.* **3**, 316–319 (2016).
125. Leclaire, R. & Bourgouin, J. Electromagnetic treatment of shoulder periarthritis: a randomized controlled trial of the efficiency and tolerance of magnetotherapy. *Arch. Phys. Med. Rehabil.* **72**, 284–287 (1991).
126. Hussein, A. Z. & Donatelli, R. A. The efficacy of radial extracorporeal shockwave therapy in shoulder adhesive capsulitis: a prospective, randomised, double-blind, placebo-controlled, clinical study. *Eur. J. Physiother.* **18**, 63–76 (2016).
127. Chen, C. Y. et al. Extracorporeal shockwave therapy improves short-term functional outcomes of shoulder adhesive capsulitis. *J. Shoulder Elb. Surg.* **23**, 1843–1851 (2014).
128. Zhang, R. et al. Extracorporeal shockwave therapy as an adjunctive therapy for frozen shoulder: a systematic review and meta-analysis. *Orthop. J. Sports Med.* **10**, 23259671211062222 (2022).
129. Page, M. J. et al. Electrotherapy modalities for adhesive capsulitis (frozen shoulder). *Cochrane Database Syst. Rev.* <https://doi.org/10.1002/14651858.CD011324> (2014).
130. Ramachandran, V. S. & Altschuler, E. L. The use of visual feedback, in particular mirror visual feedback, in restoring brain function. *Brain* **132**, 1693–1710 (2009).
131. Baskaya, M. C., Ercalick, C., Karatas Kir, O., Ercalick, T. & Tuncer, T. The efficacy of mirror therapy in patients with adhesive capsulitis: a randomized, prospective, controlled study. *J. Back Musculoskelet. Rehabil.* **31**, 1177–1182 (2018).
132. Hoffman, M. D. & Hoffman, D. R. Does aerobic exercise improve pain perception and mood? A review of the evidence related to healthy and chronic pain subjects. *Curr. Pain Headache Rep.* **11**, 93–97 (2007).
133. Leon-Latre, M. et al. Sedentary lifestyle and its relation to cardiovascular risk factors, insulin resistance and inflammatory profile. *Rev. Esp. Cardiol.* **67**, 449–455 (2014).
134. Nijs, J., Malfliet, A., Ickmans, K., Baert, I. & Meeus, M. Treatment of central sensitization in patients with ‘unexplained’ chronic pain: an update. *Expert Opin. Pharmacother.* **15**, 1671–1685 (2014).
135. van der Windt, D. A., van der Heijden, G. J., Scholten, R. J., Koes, B. W. & Bouter, L. M. The efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) for shoulder complaints. A systematic review. *J. Clin. Epidemiol.* **48**, 691–704 (1995).
136. D’Orsi, G. M., Via, A. G., Frizziero, A. & Oliva, F. Treatment of adhesive capsulitis: a review. *Muscles Ligaments Tendons J.* **2**, 70–78 (2012).
137. Jain, T. K. & Sharma, N. K. The effectiveness of physiotherapeutic interventions in treatment of frozen shoulder/adhesive capsulitis: a systematic review. *J. Back Musculoskelet. Rehabil.* **27**, 247–273 (2014).
138. Lorbach, O. et al. Nonoperative management of adhesive capsulitis of the shoulder: oral cortisone application versus intra-articular cortisone injections. *J. Shoulder Elb. Surg.* **19**, 172–179 (2010).
139. Widiastuti-Samekto, M. & Sianturi, G. P. Frozen shoulder syndrome: comparison of oral route corticosteroid and intra-articular corticosteroid injection. *Med. J. Malays.* **59**, 312–316 (2004).
140. Hettrich, C. M. et al. The effect of myofibroblasts and corticosteroid injections in adhesive capsulitis. *J. Shoulder Elb. Surg.* **25**, 1274–1279 (2016).
141. Sun, Y. et al. Intra-articular steroid injection for frozen shoulder: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. *Am. J. Sports Med.* **45**, 2171–2179 (2017).
142. Robinson, C. M., Seah, K. T., Chee, Y. H., Hindle, P. & Murray, I. R. Frozen shoulder. *J. Bone Joint Surg. Br.* **94**, 1–9 (2012).
143. Ahn, J. H. et al. Early intra-articular corticosteroid injection improves pain and function in adhesive capsulitis of the shoulder: 1-year retrospective longitudinal study. *PM R* **10**, 19–27 (2018).
144. Olafsen, N. P., Herring, S. A. & Orchard, J. W. Injectable corticosteroids in sport. *Clin. J. Sport. Med.* **28**, 451–456 (2018).
145. Walsh, L. J. et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. *Thorax* **56**, 279–284 (2001).
146. Gaujoux-Viala, C., Dougados, M. & Gossec, L. Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials. *Ann. Rheum. Dis.* **68**, 1843–1849 (2009).
147. Lim, T. K. et al. Intra-articular injection of hyaluronate versus corticosteroid in adhesive capsulitis. *Orthopedics* **37**, e860–e865 (2014).
148. Blaine, T. et al. Treatment of persistent shoulder pain with sodium hyaluronate: a randomized, controlled trial. A multicenter study. *J. Bone Joint Surg. Am.* **90**, 970–979 (2008).
149. Haque, R., Baruah, R. K., Bari, A. & Sawah, A. Is suprascapular nerve block better than intra-articular corticosteroid injection for the treatment of adhesive capsulitis of the shoulder? A randomized controlled study. *Ortop. Traumatol. Rehabil.* **23**, 157–165 (2021).
150. Jung, T. W., Lee, S. Y., Min, S. K., Lee, S. M. & Yoo, J. C. Does combining a suprascapular nerve block with an intra-articular corticosteroid injection have an additive effect in the treatment of adhesive capsulitis? A comparison of functional outcomes after short-term and minimum 1-year follow-up. *Orthop. J. Sports Med.* **7**, 2325967119859277 (2019).
151. Badalamente, M. A. & Wang, E. D. CORR(R) ORS Richard A. Brand Award: clinical trials of a new treatment method for adhesive capsulitis. *Clin. Orthop. Relat. Res.* **474**, 2327–2336 (2016).
152. Joo, Y. J. et al. A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder. *Ann. Rehabil. Med.* **37**, 208–214 (2013).
153. Nicholson, J. A., Slader, B., Martindale, A., McKie, S. & Robinson, C. M. Distension arthrogram in the treatment of adhesive capsulitis has a low rate of repeat intervention. *Bone Joint J.* **102-B**, 606–610 (2020).
154. Wu, W. T. et al. Effectiveness of glenohumeral joint dilatation for treatment of frozen shoulder: a systematic review and meta-analysis of randomized controlled trials. *Sci. Rep.* **7**, 10507 (2017).
155. Catapano, M., Mittal, N., Adamich, J., Kumbhare, D. & Sangha, H. Hydrodilatation with corticosteroid for the treatment of adhesive capsulitis: a systematic review. *PM R* **10**, 623–635 (2018).
156. Elnady, B. et al. In shoulder adhesive capsulitis, ultrasound-guided anterior hydrodilatation in rotator interval is more effective than posterior approach: a randomized controlled study. *Clin. Rheumatol.* **39**, 3805–3814 (2020).
157. Saltychev, M., Laimi, K., Virolainen, P. & Fredericson, M. Effectiveness of hydrodilatation in adhesive capsulitis of shoulder: a systematic review and meta-analysis. *Scand. J. Surg.* **107**, 285–293 (2018).
158. Ladermann, A. et al. Hydrodilatation with corticosteroids is the most effective conservative management for frozen shoulder. *Knee Surg. Sports Traumatol. Arthrosc.* **29**, 2553–2563 (2021).
159. Fitzpatrick, J., Richardson, C., Klaber, I. & Richardson, M. D. Clostridium histolyticum (AA4500) for the treatment of adhesive capsulitis of the shoulder: a randomised double-blind, placebo-controlled study for the safety and efficacy of collagenase—single site report. *Drug Des. Devel. Ther.* **14**, 2707–2713 (2020).
160. Karahan, N. et al. Can collagenase be used in the treatment of adhesive capsulitis? *Med. Princ. Pract.* **29**, 174–180 (2020).
161. Minagawa, H. Silent manipulation for frozen shoulder. *MB Orthop.* **25**, 93–98 (2012).
162. Itoi, E. & Minagawa, H. In *Shoulder Stiffness: Current Concepts and Concerns* (eds Itoi, E. et al.) 205–215 (Springer, 2015).
163. van de Laar, S. M. & van der Zwaal, P. Management of the frozen shoulder. *Orthop. Res. Rev.* **6**, 81–90 (2014).
164. Hsu, J. E., Anakwenze, O. A., Warrander, W. J. & Abboud, J. A. Current review of adhesive capsulitis. *J. Shoulder Elb. Surg.* **20**, 502–514 (2011).
165. Dodenhoff, R. M., Levy, O., Wilson, A. & Copeland, S. A. Manipulation under anesthesia for primary frozen shoulder: effect on early recovery and return to activity. *J. Shoulder Elb. Surg.* **9**, 23–26 (2000).
166. Reichmister, J. P. & Friedman, S. L. Long-term functional results after manipulation of the frozen shoulder. *Md Med. J.* **48**, 7–11 (1999).
167. Arce, G., Di Giacomo, G. & Chen, J. In *Shoulder Stiffness: Current Concepts and Concerns* (eds Itoi, E. et al.) 217–225 (Springer, 2015).
168. Barnes, C. P., Lam, P. H. & Murrell, G. A. Short-term outcomes after arthroscopic capsular release for adhesive capsulitis. *J. Shoulder Elb. Surg.* **25**, e256–e264 (2016).
169. Berghs, B. M., Sole-Molins, X. & Bunker, T. D. Arthroscopic release of adhesive capsulitis. *J. Shoulder Elb. Surg.* **13**, 180–185 (2004).
170. Le Lievre, H. M. & Murrell, G. A. Long-term outcomes after arthroscopic capsular release for idiopathic adhesive capsulitis. *J. Bone Joint Surg. Am.* **94**, 1208–1216 (2012).
171. Segmuller, H. E., Taylor, D. E., Hogan, C. S., Saies, A. D. & Hayes, M. G. Arthroscopic treatment of adhesive capsulitis. *J. Shoulder Elb. Surg.* **4**, 403–408 (1995).
172. Warner, J. J., Allen, A., Marks, P. H. & Wong, P. Arthroscopic release for chronic, refractory adhesive capsulitis of the shoulder. *J. Bone Joint Surg. Am.* **78**, 1808–1816 (1996).
173. Diwan, D. B. & Murrell, G. A. An evaluation of the effects of the extent of capsular release and of postoperative therapy on the temporal outcomes of adhesive capsulitis. *Arthroscopy* **21**, 1105–1113 (2005).
174. Rangan, A. et al. Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial. *Lancet* **396**, 977–989 (2020).
- Pivotal randomized controlled trial comparing MUA, physiotherapy and arthroscopic surgery in frozen shoulder.**
175. King, W. V. & Hebron, C. Frozen shoulder: living with uncertainty and being in “no-man’s land”. *Physiother. Theory Pr.* **14**, 1–15 (2022).
176. Mulligan, E. P., Brunette, M., Shirley, Z. & Khazzam, M. Sleep quality and nocturnal pain in patients with shoulder disorders. *J. Shoulder Elb. Surg.* **24**, 1452–1457 (2015).
177. Toprak, M. & Erden, M. Sleep quality, pain, anxiety, depression and quality of life in patients with frozen shoulder. *J. Back Musculoskelet. Rehabil.* **32**, 287–291 (2019).
178. Ebrahimzadeh, M. H., Moradi, A., Bidgoli, H. F. & Zarei, B. The relationship between depression or anxiety symptoms and objective and subjective symptoms of patients with frozen shoulder. *Int. J. Prev. Med.* **10**, 38 (2019).
179. Lubis, A. M. & Lubis, V. K. Matrix metalloproteinase, tissue inhibitor of metalloproteinase and transforming growth factor-beta 1 in frozen shoulder, and their changes as response to intensive stretching and supervised neglect exercise. *J. Orthop. Sci.* **18**, 519–527 (2013).
180. Xue, M., Gong, S., Dai, J., Chen, G. & Hu, J. The treatment of fibrosis of joint synovium and frozen

- shoulder by Smad4 gene silencing in rats. *PLoS ONE* **11**, e0158093 (2016).
181. Warburton, D. E., Nicol, C. W. & Bredin, S. S. Prescribing exercise as preventive therapy. *CMAJ* **174**, 961–974 (2006).
182. Gregg, E. W., Gerzoff, R. B., Caspersen, C. J., Williamson, D. F. & Narayan, K. M. Relationship of walking to mortality among US adults with diabetes. *Arch. Intern. Med.* **163**, 1440–1447 (2003).
183. Dunstan, D. W. et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)—methods and response rates. *Diabetes Res. Clin. Pract.* **57**, 119–129 (2002).
184. McLeod, J. C., Stokes, T. & Phillips, S. M. Resistance exercise training as a primary countermeasure to age-related chronic disease. *Front. Physiol.* **10**, 645 (2019).
185. Maestroni, L. et al. The benefits of strength training on musculoskeletal system health: practical applications for interdisciplinary care. *Sports Med.* **50**, 1431–1450 (2020).
186. Dean, E. & Soderlund, A. What is the role of lifestyle behaviour change associated with non-communicable disease risk in managing musculoskeletal health conditions with special reference to chronic pain? *BMC Musculoskelet. Disord.* **16**, 87 (2015).
187. Ramiro, S. et al. The OMERACT core domain set for clinical trials of shoulder disorders. *J. Rheumatol.* **46**, 969–975 (2019).

Author contributions

Introduction (N.L.M., G.A.C.M. and S.A.R.); Epidemiology (N.L.M., E.W., A.L.C. and P.D.K.); Mechanisms/pathophysiology (N.L.M., L.M., S.A.R., M.A., A.L.C. and G.A.C.M.); Diagnosis, screening and prevention (A.M., F.S. and E.W.); Management (N.L.M., A.L.C., A.M., F.S., E.W., P.D.K., G.A.C.M., J.C.R. and S.A.R.); Quality of life (N.L.M. and P.D.K.); Outlook (N.L.M., M.A., S.A.R. and A.L.C.); Overview of Primer (N.L.M.).

Competing interests

The authors declare no competing interests.

Peer review information

Nature Reviews Disease Primers thanks P. J. Millett; C. P. Charalambous; M.-M. Lefevre-Colau, who co-reviewed with A. Roren; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

© Springer Nature Limited 2022